Infectious Disease Phase 1 Deal Benchmarks — China (2026)
Median upfront of $20M with total deal values reaching $169M in China territory.
Median Upfront
$20M
Total Deal Value
$121M
Royalty Range
3%–5.9%
Territory Multiplier
0.12x
Understanding Infectious Disease Deal Benchmarks at Phase 1
Phase 1 Infectious Disease licensing deals in China territory command a median upfront payment of $20M, with values ranging from $10M at the low end to $30M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $73M to $169M, with a median of $121M. Royalty rates for infectious disease assets at this stage typically fall between 3% and 5.9% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The China territory applies a 0.12x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating china rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $10M | $20M | $30M |
| Total Deal Value | $73M | $121M | $169M |
| Royalty Rate | 3% | — | 5.9% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | VBI Vaccines | Brii Biosciences | $25M | $200M | licensing |
| 2023 | Arbutus Biopharma | Qilu Pharmaceutical | $40M | $300M | licensing |
See All Comparable Deals
View 2 comparable Infectious Disease transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Infectious Disease deals in China territory?
How does China territory affect Infectious Disease deal value?
What royalty rates are typical for Phase 1 Infectious Disease licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$8M upfront
Infectious Disease · Preclinical · China
$61M upfront
Infectious Disease · Phase 2 · China
$153M upfront
Infectious Disease · Phase 3 · China
$435M upfront
Infectious Disease · Approved · China
$11M upfront
Oncology · Phase 1 · China
$9M upfront
Neurology/CNS · Phase 1 · China
$20M upfront
Immunology · Phase 1 · China
$27M upfront
Metabolic/Obesity · Phase 1 · China
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Infectious Disease Phase 1 Deal Benchmarks — China (2026). Retrieved from https://solidus.ambrosiaventures.co/data/infectious-disease-phase-1-deals-china
<a href="https://solidus.ambrosiaventures.co/data/infectious-disease-phase-1-deals-china">Infectious Disease Phase 1 Deal Benchmarks — China (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=infectiousDisease&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.